Annals of Allergy Asthma & Immunology最新文献

{"title":"How we treat severe atopic dermatitis","authors":"Ellen Chinchilli BA , Anna De Benedetto MD , Lisa A. Beck MD","doi":"10.1016/j.anai.2025.03.005","DOIUrl":"10.1016/j.anai.2025.03.005","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 660-663"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantifying corticosteroid burden in chronic rhinosinusitis with nasal polyps","authors":"Joseph K. Han MD ,&nbsp;Jared Silver MD ,&nbsp;Indu Dhangar BDS ,&nbsp;Phani Veeranki MD, DrPH ,&nbsp;Arijita Deb PhD","doi":"10.1016/j.anai.2024.10.015","DOIUrl":"10.1016/j.anai.2024.10.015","url":null,"abstract":"<div><h3>Background</h3><div>Real-world burden data on systemic corticosteroid (SCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) are limited.</div></div><div><h3>Objective</h3><div>To describe the real-world burden of SCS in CRSwNP.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included commercial/Medicare Advantage with Part D health plan members from the Optum Research Database with a first medical claim (index) for CRSwNP (January 2015-July 2020). Primary outcomes/variables included SCS use, health care resource utilization, and costs during the 12-month follow-up period. Outcomes were analyzed overall (N = 21,172) and stratified by baseline comorbid asthma status and sinus surgeries during follow-up.</div></div><div><h3>Results</h3><div>Overall, 64.7% and 41.0% of patients used all-cause and CRSwNP-related SCS, respectively, and 36.0% had ≥1 oral corticosteroid (OCS) burst (≥20 mg for 3-28 days); SCS use was higher in patients with asthma and those with a NP-related surgery (1, 2, and ≥3) vs without. The mean (SD) all-cause cumulative oral corticosteroid dose was 303.3 (675.0) mg/year and 23.5% had a cumulative annual dose ≥400 mg; these values were higher (<em>P</em> &lt; .001) in patients with vs without comorbid asthma (514.9 [956.1] vs 247.5 [567.0]; 36.9% vs 19.9%). All-cause and CRSwNP health care resource utilization and costs increased with increasing number of surgeries; mean (SD) all-cause total medical costs were $14,472 (38,915), $26,909 (40,800), $29,816 (41,677), and $31,558 (37,143) with 0, 1, 2, and ≥3 surgeries, respectively.</div></div><div><h3>Conclusion</h3><div>These data highlight the significant burden of SCS use in CRSwNP, particularly in patients with comorbid asthma, and suggest a need to reduce SCS exposure.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 685-693.e5"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in real life","authors":"Robert Greig MBChB,&nbsp;Rory Chan PhD,&nbsp;Brian J. Lipworth MD","doi":"10.1016/j.anai.2025.03.013","DOIUrl":"10.1016/j.anai.2025.03.013","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 732-734"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRISPR Bomb Squad","authors":"Erin L. Reigh MD, MS","doi":"10.1016/j.anai.2025.02.004","DOIUrl":"10.1016/j.anai.2025.02.004","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 658-659"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors’ response","authors":"Patrick K. Gleeson MD, MSCE ,&nbsp;Knashawn H. Morales ScD ,&nbsp;Meeta Prasad Kerlin MD, MSCE ,&nbsp;Olajumoke O. Fadugba MD ,&nbsp;Andrea J. Apter MD, MSc, MA ,&nbsp;Jason D. Christie MD, MSCE ,&nbsp;Blanca E. Himes PhD","doi":"10.1016/j.anai.2025.03.026","DOIUrl":"10.1016/j.anai.2025.03.026","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Page 740"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic and mechanistic advances in chronic cough","authors":"Anju T. Peters MD, MS ,&nbsp;Ken W. Altman MD, PhD ,&nbsp;Peter Dicpinigaitis MD ,&nbsp;Matthew G. Drake MD ,&nbsp;Imran Satia MD, PhD ,&nbsp;Gayatri B. Patel MD, MS","doi":"10.1016/j.anai.2024.12.021","DOIUrl":"10.1016/j.anai.2024.12.021","url":null,"abstract":"<div><div>Cough is one of the most common reasons patients seek medical care in the outpatient setting. Chronic cough (CC) in adults is defined as a cough lasting more than 8 weeks, with a global prevalence of approximately 10%. CC significantly impairs quality of life, affecting physical, social, and psychological well-being. In most cases, CC is attributed to 1 or more of the following 3 key conditions: upper airway cough syndrome, gastroesophageal or laryngopharyngeal reflux, and asthma or non-asthmatic eosinophilic bronchitis—assuming a normal chest x-ray result and no use of angiotensin-converting enzyme inhibitors. If the cough persists despite thorough guideline-based evaluation and treatment, it is classified as refractory CC (RCC). RCC is thought to arise from neuronal dysregulation involving both peripheral and central mechanisms, termed cough hypersensitivity syndrome. This is typically characterized by a tickle or itch sensation in the throat, leading to an urge to cough in response to seemingly harmless stimuli. Current treatment options for RCC include “off-label” use of centrally acting neuromodulators and speech therapy. In addition, a new peripherally acting oral P2×3 receptor antagonist, gefapixant, has been approved in the European Union, United Kingdom, Switzerland, and Japan, though not in the United States or Canada. Emerging treatments hold promise for improving management in the future.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 639-648"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated oxidative stress and steroid insensitivity in patients with asthma and high body fat percentage","authors":"Masako To MD, PhD ,&nbsp;Yoshihito Arimoto MD ,&nbsp;Natsue Honda MD, PhD ,&nbsp;Naho Furusho MD ,&nbsp;Toru Kinouchi MD, PhD ,&nbsp;Yuichiro Takeshita MD ,&nbsp;Kosuke Haruki MD, PhD ,&nbsp;Yasuo To MD, PhD","doi":"10.1016/j.anai.2025.03.009","DOIUrl":"10.1016/j.anai.2025.03.009","url":null,"abstract":"<div><h3>Background</h3><div>Obesity is a risk factor for poor asthma control. Previous research suggests that patients with asthma and obesity have reduced responsiveness to corticosteroids. Recent studies indicate that body fat percentage may be more strongly associated with obesity-related diseases compared with body mass index. However, the relationship between body fat percentage and asthma, particularly regarding steroid sensitivity, remains unclear.</div></div><div><h3>Objective</h3><div>To investigate the association between body fat percentage and steroid sensitivity in patients with asthma and elucidate the potential mechanisms underlying this association.</div></div><div><h3>Methods</h3><div>Adult patients with asthma were enrolled and categorized into patients with high body fat percentage (HBF) and control groups. Peripheral blood mononuclear cells were isolated from the blood samples. These cells were cultured with dexamethasone followed by stimulation with tumor necrosis factor-α to assess the half-maximal inhibitory concentration of dexamethasone (IC₅₀-Dex). Serum adipocytokines and oxidative stress markers were also measured. The effects of metformin on steroid sensitivity and oxidative stress in peripheral blood mononuclear cells were evaluated ex vivo.</div></div><div><h3>Results</h3><div>The HBF group exhibited significantly higher IC₅₀-Dex values than the control group. In the HBF group, IC₅₀-Dex correlated with the number of acute exacerbations per year and serum oxidative stress marker levels. Treatment with metformin significantly reduced both IC₅₀-Dex and oxidative stress marker levels in the HBF group.</div></div><div><h3>Conclusion</h3><div>Oxidative stress associated with increased body fat may contribute to impaired steroid sensitivity in patients with asthma. Metformin may improve steroid sensitivity by reducing oxidative stress, suggesting a potential therapeutic approach in this patient population.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 664-670"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric validation of the Standard Tests for Asthma, Allergic Rhinitis, and Chronic Rhinosinusitis in the United States","authors":"Mandy K. Salmon MD ,&nbsp;Priya Arya BS ,&nbsp;Vibeke Backer MD, DMSci ,&nbsp;Kasper Aanaes MD, PhD ,&nbsp;Christian Korsgaard Pedersen MD ,&nbsp;Johan Hellgren PhD ,&nbsp;Christian von Buchwald MD, DMSci ,&nbsp;James N. Palmer MD","doi":"10.1016/j.anai.2025.02.016","DOIUrl":"10.1016/j.anai.2025.02.016","url":null,"abstract":"<div><h3>Background</h3><div>Chronic rhinosinusitis with nasal polyposis is an inflammatory disease associated with type 2 inflammation, which is present in lower airway disease (asthma). Current tools used to track symptoms and quality-of-life burden of disease, such as the 22-item Sinonasal Outcome Test (SNOT-22), lack specificity in the symptoms evaluated.</div></div><div><h3>Objective</h3><div>To combat this shortcoming, we validated a new survey, Standard Tests for Asthma, Allergic Rhinitis, and Chronic Rhinosinusitis (STARR-15), in a population of US patients with chronic rhinosinusitis with nasal polyposis.</div></div><div><h3>Methods</h3><div>In this project, STARR-15 was tested in a population of patients with chronic rhinosinusitis with nasal polyposis at a single tertiary care center in the United States. The survey was also compared with a corresponding population of patients with chronic rhinosinusitis without nasal polyps from the same institution.</div></div><div><h3>Results</h3><div>The survey was assessed within the population of patients with chronic rhinosinusitis with nasal polyposis and found to demonstrate good test-retest reliability with an intraclass correlation coefficient of 0.93. The survey was internally valid, with Cronbach alpha of 0.85. Furthermore, the survey was assessed for external validity by comparing it with the SNOT-22. STARR-15 correlated positively with the SNOT-22, with a Pearson coefficient of 0.77.</div></div><div><h3>Conclusion</h3><div>This work has implications in helping follow patient symptoms over time for patients who have not only chronic rhinosinusitis with nasal polyps but also other inflammatory conditions of the lower airways. It also has potential to be used as a screening tool for patients with chronic rhinosinusitis, asthma, and allergic rhinitis.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 671-675"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using claims data to supplement the shared decision-making process in chronic rhinosinusitis with nasal polyps","authors":"Gary C. Steven MD, PhD","doi":"10.1016/j.anai.2025.02.024","DOIUrl":"10.1016/j.anai.2025.02.024","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 624-625"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of food allergic reactions among adolescents engaged in food allergy management","authors":"Roxanne Dupuis PhD ,&nbsp;Jonathan M. Spergel MD, PhD ,&nbsp;Terri F. Brown-Whitehorn MD ,&nbsp;Andrea B. Troxel ScD ,&nbsp;Erica L. Kenney ScD ,&nbsp;Jason P. Block MD ,&nbsp;Rachel Feuerstein-Simon MPA, MPH ,&nbsp;Xochitl Luna Marti MPH ,&nbsp;Cynthia J. Mollen MD ,&nbsp;Zachary F. Meisel MD ,&nbsp;Kevin G. Volpp MD, PhD ,&nbsp;Steven L. Gortmaker PhD ,&nbsp;Carolyn C. Cannuscio ScD","doi":"10.1016/j.anai.2025.02.023","DOIUrl":"10.1016/j.anai.2025.02.023","url":null,"abstract":"<div><h3>Background</h3><div>Although fatal food-induced anaphylaxis is rare, adolescence is the period of highest risk. However, we lack strong estimates of the incidence of food allergic reactions among adolescents.</div></div><div><h3>Objective</h3><div>To estimate the incidence of food allergic and anaphylactic reactions among adolescents with food allergy who have a prescription for epinephrine.</div></div><div><h3>Methods</h3><div>As part of a cohort study that was embedded in a randomized trial to promote safe food allergy management, we followed adolescents aged 15 to 19 years with food allergy and a current prescription for epinephrine for a period of 15 months in 2019 to 2020. At monthly intervals, participants were asked, through text message check-ins, whether they had experienced a food allergic reaction due to accidental exposure to food allergens in the past month.</div></div><div><h3>Results</h3><div>Among the cohort of 131 adolescents, 112 answered at least 1 of the 15 monthly check-ins. Together, these respondents contributed 742 person-months of follow-up data of a total possible 1680 person-months. In the 15-month study period, the incidence of food allergic reactions among adolescents with food allergy was 34.0 events per 100 person-years (95% CI: 21.0-51.9). The incidence of food allergic reactions meeting the criteria for anaphylaxis was 16.2 events per 100 person-years (95% CI: 7.8-29.7).</div></div><div><h3>Conclusion</h3><div>Data on the incidence of food allergic reactions can help set expectations for safe food allergy management for adolescents and their families, and can help inform discussions between patients, families, and physicians regarding different treatment options available and their associated risks and benefits.</div></div><div><h3>Trial Registration</h3><div>ClinicalTrials.gov Identifier: NCT03284372.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 719-723.e2"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}